Levaler

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levaler

Quick Facts: Levaler (Levocetirizine)

Property Description
Active Ingredient Levocetirizine dihydrochloride
Forms Film-coated tablets, Oral solution
Pharmacological Class Second-Generation Antihistamine
General Use Systemic anti-allergic relief
Origin Synthetic derivative (R-enantiomer)

Identity and Pharmacological Classification

Levaler is a pharmaceutical product containing Levocetirizine dihydrochloride as its core active ingredient. It is precisely classified as a Second-Generation Histamine H1 Receptor Antagonist, which places it within the general class of antihistamine medications used to counter allergic responses.

The compound is a synthetic derivative distinguished as the isolated, biologically active R-enantiomer of cetirizine. This specific chemical structure is clinically recognized for its high affinity for peripheral H1 receptors. The targeted selectivity of this compound provides more consistent and effective relief from allergy symptoms compared to older, non-selective compounds.


Composition and General Therapeutic Purpose

Levaler is a single-ingredient product, featuring only Levocetirizine dihydrochloride, and is designed for the oral route of administration. It is supplied in two primary dosage forms: film-coated tablets and a liquid oral solution. The availability of both solid and liquid forms, with the solution incorporating the active compound in an aqueous vehicle, provides flexibility for various user groups.

The primary purpose is achieved through its potent blocking mechanism: Levocetirizine competitively occupies the H1 receptors, thereby preventing the body's natural release of histamine from initiating allergic effects. The overarching therapeutic benefit is the suppression of the biological chain reaction, minimizing the physical symptoms associated with an allergic reaction, such as itching, swelling, and increased mucus production.

What side effects are possible with Levaler?

Possible Side Effects and Safety Information

The safety profile for Levaler (Levocetirizine dihydrochloride) is based on official government regulatory documents. Adverse reactions are formally classified by frequency and associated with specific organ systems in the body.

Documented Adverse Reactions

Side effects reported in clinical trials and post-marketing surveillance are grouped by their frequency of occurrence:

Classification Example Adverse Reaction
Common (1 in 10 to 1 in 100 people) Somnolence (Drowsiness), Fatigue, Dry mouth
Uncommon (1 in 100 to 1 in 1,000 people) Asthenia (Loss of strength), Abdominal pain

Post-marketing reports also document reactions with a Not Known frequency, including Hypersensitivity (such as Anaphylaxis), Convulsion, Aggression, Suicidal Ideation, and Urinary Retention.

Serious Safety Considerations

The official labeling notes that Levaler is substantially excreted by the kidneys. It is contraindicated in individuals with End-Stage Renal Disease (severe kidney impairment) and in certain pediatric patients with any degree of renal impairment, as the risk of adverse reactions is greater in these populations.

Safety constraints also address mental alertness: due to the potential for drowsiness, use with alcohol or other Central Nervous System (CNS) depressants should be avoided. Caution is advised when engaging in activities that require complete mental alertness, such as operating machinery or driving.

A duration-related safety pattern has also been documented: severe pruritus (itching) upon discontinuation has been reported following the cessation of long-term daily use of the medicine.

Overdose and Emergency Response

Overdose Symptoms

Taking more than the prescribed dose of Levaler (levocetirizine) can lead to an overdose. The symptoms vary between adults and children. In adults, the primary symptom is typically increased drowsiness.

In young children, an overdose may present as a period of agitation and restlessness, which is then commonly followed by increased drowsiness.

Less frequent, but more serious, symptoms associated with antihistamine overdose can include:

  • Rapid heartbeat (tachycardia)
  • Confusion
  • Seizures

When to Seek Help

If you suspect that you or someone else has taken too much Levaler, seek immediate emergency medical attention. Do not wait for symptoms to become severe. Overdose treatment is supportive and may involve monitoring vital signs, administering activated charcoal to reduce drug absorption, and treating specific symptoms.

Immediately call a poison control center or your local emergency number if any of the following severe symptoms occur:

  • Difficulty breathing
  • Uncontrollable shaking (seizures)
  • Loss of consciousness or difficulty waking up
  • Signs of a severe allergic reaction (e.g., swelling of the face, tongue, or throat)

Therapeutic Uses of Levaler

What Levaler Treats: Main Uses and Benefits

Levaler is commonly used for managing conditions characterized by periods of heightened symptoms associated with allergic reactions. This is applied across therapeutic domains where additional symptomatic support is needed for both allergic rhinitis (seasonal and perennial forms) and the uncomplicated skin symptoms of chronic idiopathic urticaria (hives). The medication is indicated for the relief of symptoms associated with these conditions.

The medication helps address symptom clusters that may become intense or disruptive, such as frequent sneezing, persistent runny nose, nasal itching, and itchy, watery eyes. It is also relevant for easing the discomfort of recurrent skin manifestations, including bothersome chronic pruritus (itching) and temporary welts (wheals). This assists with easing the overall symptom load during periods of increased distress.

“The medication is considered relevant for offering symptomatic relief that may assist with maintaining functional stability.”


Quick Fact: Relief for Allergic Discomfort

Symptom Type Context of Use Primary Benefit
Nasal/Ocular Seasonal and year-round exposure Contributes to easing respiratory discomfort
Cutaneous Recurrent chronic hives (CIU) Helps ease skin itching and discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Levaler?

This section explains population eligibility for Levaler (levocetirizine) based strictly on official regulatory labeling. Eligibility is primarily defined by age, kidney function, and known allergies.


Populations Excluded from Use

Classification Who Must Not Use Levaler
Absolute Contraindication Patients with known hypersensitivity to levocetirizine, cetirizine, or any other piperazine derivatives.
Severe Renal Disease Patients with End-Stage Renal Disease (ESRD) (creatinine clearance <10 mL/min).
Pediatric Renal Impairment Children aged 6 months to 11 years with any degree of impaired renal function.

Age-Specific Eligibility

  • Infants: Safety and efficacy are not established for infants younger than 6 months of age.
  • Children and Adolescents: The oral solution is approved starting at 6 months of age. Tablets are generally reserved for those 6 years and older.
  • Adults: Approved for use. However, individuals with mild to severe renal impairment require an adjustment to the dosing interval.

Caution is also recommended for patients with predisposing factors for urinary retention or those with epilepsy due to an increased risk of convulsions.

What should I know about interactions with other medicines?

Levaler Interactions with other medicines and products

Official regulatory information describes specific interaction patterns related to the elimination of Levaler and its pharmacodynamic activity. Due to the medication being predominantly excreted by the kidneys, its interaction profile is significantly constrained by renal clearance.


Official Interaction Statements

Interaction Type Interacting Substance/Condition Regulatory Documentation Status
Pharmacodynamic Alcohol or other CNS Depressants Avoid concurrent use; may cause additive impairment of Central Nervous System performance.
Pharmacokinetic Ritonavir Documented effect resulting in a small decrease in Levaler's clearance.
Pharmacokinetic Theophylline (low dose) Documented effect resulting in a small decrease in the clearance of the parent compound (cetirizine).
Population-Specific End-Stage Renal Disease (CrCl < 10 mL/min) Contraindicated due to the inability to eliminate the drug, leading to exposure increase.

Documented Lack of Interaction

Regulatory assessments indicate that Levaler is unlikely to produce or be subject to metabolic interactions involving major hepatic CYP enzyme systems. Furthermore, no clinically relevant interaction is documented between Levaler and food or non-alcoholic beverages.

These official statements define a profile where dosage adjustment is required in patients with less severe renal impairment to manage the exposure risk, while co-use with CNS depressants is restricted due to additive effects.

Mechanism of Action

Levaler functions as a selective modulator, exerting its activity on a defined subset of [Specific Receptor Type] located within the central and peripheral nervous systems. Its molecular structure allows for a targeted interaction, influencing the receptor's conformation and subsequent signaling ability. This action initiates the drug's physiological effect by directly intervening in the transmission of specific chemical messengers.

Following this binding, Levaler's activity is propagated through well-characterized signal transduction cascades. The drug modifies the activity of key intracellular mediators, altering phosphorylation status or second messenger levels within the target cells. This influence over the molecular cascades limits the downstream physiological effects of heightened or dysregulated signaling.

Through its combined action of targeted receptor modulation and altered signal transduction, Levaler contributes to normalizing or dampening excessive activity within specific central and/or peripheral pathways. The drug's mechanism aims to counteract the dominance of specific mediators associated with hyperactivity in defined neural circuits, shaping the resulting physiological effect toward a modulated signaling state.

Dosage and Administration Information

Official Administration Guidelines for Levaler

Levaler (levocetirizine) is a single-ingredient product designed for oral administration using either the 5 mg film-coated tablet or the 2.5 mg/5 mL oral solution. The administration schedule is strictly once daily and is recommended to be taken in the evening, which helps establish the required systemic pattern. The medicine can be taken without regard to food consumption.


Labeled Dosing Regimens

Age Group (Starting 12 Years Old) Recommended Daily Dose
Adults and Adolescents 5 mg once daily (Maximum dose)
Adults (Alternative Dose) 2.5 mg once daily (Half a scored tablet)
Children 6 to 11 Years 2.5 mg once daily
Children 6 Months to 5 Years 1.25 mg (Oral solution) once daily

Procedural and Adjustment Instructions

Precise dosing is required for specific populations. For instance, the 5 mg tablet is scored to allow for the administration of the 2.5 mg dose. The dose should not be exceeded in children, as this may result in higher systemic exposure compared to adults.

Renal Impairment Adjustment: Because Levaler is substantially excreted by the kidneys, specific dose adjustments are required for adults and adolescents ( 12 years) with decreased renal function. For example, in mild renal impairment (CrCl 50-80 mL/min), the recommended dose is reduced to 2.5 mg once daily. Further reductions in frequency are required for moderate or severe impairment.

If a dose is missed, the procedure is to take it as soon as remembered, but if it is almost time for the next scheduled dose, the missed dose should be skipped; doses should not be doubled to make up for a missed one.


This structured usage protocol focuses on standardized dosing and adherence to frequency, with adjustments based on a patient's renal clearance rate.

Recent Clinical Evidence

Research evidence / Overview of studies for Levaler (Levocetirizine)


The research base for Levaler primarily relies on Randomized Controlled Trials (RCTs) across conditions characterized by fluctuating symptoms, including Allergic Rhinitis (seasonal and perennial). Studies examined outcomes related to physical discomfort and daily functioning using patient-reported scores for symptoms like sneezing and nasal itching. Findings generally described symptom score patterns that differed from those observed with an inactive substance (placebo).

For Chronic Idiopathic Urticaria (Hives), evidence was derived from trials focusing on uncomplicated skin manifestations. Studies monitored patient-reported measures like the severity of itching and the number of wheals. Findings in these studies described patterns related to differences in the measured symptom scores.

Long-Term Research has been evaluated in defined intervals, with follow-up durations extending up to six months in certain chronic condition trials. However, many initial efficacy trials had short follow-up durations, meaning that the stability of measured outcomes beyond intermediate periods remains an area of limited information. Regulatory bodies have noted that research has explored rare reports of severe itching (pruritus) after the discontinuation of long-term daily use of this medicine, highlighting an area of ongoing study related to the effects of cessation.

Evidence in Special Populations included studies on pediatric groups as young as 6 months. Specialized pharmacokinetic studies in older adults and individuals with impaired kidney function have indicated altered drug disposition. Studies observed patterns related to altered clearance in individuals with kidney issues, providing information on pharmacokinetic patterns in these specific populations.

Identified Research Gaps include a lack of standardized long-term head-to-head trials against every other similar medicine. Data for specific subgroups remain insufficient, and certainty remains low in areas where long-term effects are not fully established.

Key Studies & References

  1. Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency (Observational Study)
  2. Xyzal 5mg Film-coated Tablets - Summary of Product Characteristics (SPC) - European Regulatory Data

Frequently Asked Questions (FAQ)

Common questions about Levaler (FAQ)


Q: Is Levaler a painkiller or something else?

A: Official regulatory documents classify Levaler as a second-generation H1-antihistamine. The medication is used to prevent the effects of histamine in the body, which helps relieve symptoms associated with allergies, such as sneezing, itching, and runny nose. It is important to note that the product is not described as a painkiller (analgesic) in official labeling.


Q: How quickly does Levaler typically start working after the first dose?

A: Clinical studies have examined the speed of its antihistaminic effect. Official product information indicates that the drug's activity, measured by skin testing, is observed to persist for at least 24 hours after a standard dose. The specific time until you notice symptom relief is not detailed in the general labeling.


Q: Does Levaler interact with herbal supplements like St. John's Wort?

A: Official documents do not specifically list St. John's Wort as a documented interaction. Levaler is primarily eliminated by the kidneys, and regulatory assessments indicate it is generally unlikely to be involved in metabolic interactions involving the major liver enzyme systems (CYP).


Q: Does Levaler affect birth control pills?

A: Regulatory assessments indicate the drug is unlikely to be involved in metabolic interactions with the major liver enzyme systems. Due to this profile, there are no specific, clinically relevant interactions documented in official labeling regarding oral contraceptives.


Q: What does the research say about the long-term use of Levaler?

A: Research includes efficacy trials with follow-up periods up to six months. Regulatory bodies have noted reports of severe itching (pruritus) that have been observed when stopping the medicine after long-term daily use. This is noted as an area of safety monitoring.


Q: Does Levaler affect sleep patterns?

A: Common adverse reactions documented in clinical trials include drowsiness (somnolence) and fatigue. Less common reports, especially when the drug is used with alcohol or other CNS depressants, have included unusual dreams and trouble sleeping. Official warnings advise caution when engaging in activities that require full mental alertness, such as driving or operating heavy machinery.


Q: Can Levaler be used during pregnancy or while breastfeeding?

A: Official labeling advises consulting a healthcare professional before use if you are pregnant. For breastfeeding, official labeling indicates that use is not recommended.


Q: Do studies suggest Levaler's effectiveness decreases over time?

A: Official long-term research data on the stability of measured outcomes is limited for periods beyond six months. Regulatory documents do not contain statements indicating that the effectiveness of the medicine decreases with continued use, known as tachyphylaxis.


Q: Is Levaler known to cause weight gain or weight loss?

A: Official documents do not list weight gain or weight loss as a common or uncommon side effect associated with the medication. However, official adverse reaction reports have noted increased appetite as a less common event.


Q: Is Levaler considered a controlled substance?

A: Official regulatory documentation states that Levaler is not classified as a controlled substance and is not subject to the Controlled Substances Act in the United States.


Q: Is there a generic version of Levaler available?

A: Yes, the active ingredient in Levaler, levocetirizine dihydrochloride, is available in generic form.


Q: Can I take Levaler if I am currently taking aspirin?

A: Official drug interaction assessments have found no documented interaction between levocetirizine and low-strength aspirin.


Q: Is Levaler addictive or habit-forming?

A: Levaler is not classified as a controlled substance by regulatory bodies. Official documents do note the physical reaction of severe itching (pruritus) upon stopping the drug after long-term use.


Q: Why is Levaler sometimes described as a 'first-line treatment'?

A: Authoritative medical literature describes the class of medications known as H1-antihistamines as a traditional first-line treatment option. This refers to its place in treatment strategies for conditions like allergic rhinitis and chronic hives.


Q: Is it possible to be allergic to an ingredient in Levaler?

A: Yes. Official labeling includes a warning against the use of the medicine if a patient has ever had an allergic reaction to the active ingredient, the related compound cetirizine, or any of its listed inactive ingredients (excipients).


Q: Can men and women expect different effects from Levaler?

A: Pharmacokinetic studies have examined differences in how the drug is processed by the body in men versus women. These studies describe that the effect of gender on how the drug is processed by the body is not clinically significant at the usual daily dose.


Q: Is the purpose of Levaler different depending on the country?

A: The active ingredient, levocetirizine dihydrochloride, is consistently approved worldwide for the systemic relief of symptoms associated with allergic conditions, such as chronic hives and allergic rhinitis.


Q: Are there any commonly confused medications with Levaler?

A: Levaler is the isolated, biologically active component (the R-enantiomer) of the related, commonly known antihistamine cetirizine. Both belong to the class of second-generation H1-antihistamines, which may lead to confusion.


Q: Is Levaler part of a class of medications with a specific safety warning?

A: Regulatory bodies have issued a safety communication concerning the risk of severe itching (pruritus) upon discontinuation of long-term daily use of both levocetirizine and its parent compound, cetirizine.


Q: What should I do if a side effect of Levaler feels severe or unusual?

A: Official guidance indicates that stopping use and immediately seeking medical help is required if an allergic reaction occurs or if specific severe symptoms, such as trouble urinating, are experienced. Patients are generally advised to report any other troublesome side effects.


Q: What kind of monitoring is typically required while taking Levaler?

A: Official instructions require dose adjustments based on a patient's kidney function (renal clearance rate) in certain populations. General symptom monitoring is also usually recommended to assess the drug's intended benefit.


Q: What other drugs belong to the same class as Levaler?

A: Levaler belongs to a class of medications called second-generation H1-antihistamines. This class includes other related products, such as desloratadine, fexofenadine, and loratadine, which are also used for allergic conditions.


Q: Are there any restrictions on activity while taking this medicine?

A: Official warnings advise caution regarding activities that require full mental alertness, such as driving a motor vehicle or operating heavy machinery. This caution is advised due to the potential for drowsiness and impaired coordination, which are common adverse effects.

How should Levaler be stored and disposed of?

Storage Requirements

Official labeling mandates that Levaler (levocetirizine dihydrochloride) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Temporary temperature excursions are permitted up to 30 C.

Storage must protect the product from excess heat and moisture, and the medication should be kept in the container it came in, tightly closed, with the safety seal intact. Crucially, the product must be kept out of reach of children for safety, which includes storing it in an 'up and away' location.

Disposal Instructions

Regulatory guidance requires that any unused or expired Levaler must be disposed of in accordance with local requirements. Official instructions generally advise against throwing medicine directly into household waste without preparation. Instead, unused medicine should be mixed with an unappealing substance, sealed in a container, and then placed in the trash, or taken to an authorized drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levaler found in:

A-Z Index: